Short-Term Responders of NSCLC to EGFR-TKIs Display High Prevalence of TP53 Mutations and Primary Resistance Mechanisms

被引：0

作者：

Xu, Y. ^{[1
]}

Tong, X. ^{[2
]}

Yan, J. ^{[3
]}

Wu, X. ^{[2
]}

Shao, Y. W. ^{[2
]}

Fan, Y. ^{[4
]}

机构：

[1] Zhejiang Canc Hosp, Chemotherapy, Hangzhou, Zhejiang, Peoples R China

[2] Geneseeq Technol Inc, Translat Med Res Inst, Toronto, ON, Canada

[3] Nanjing Geneseeq Technol Inc, Med Dept, Nanjing, Jiangsu, Peoples R China

[4] Zhejiang Canc Hosp, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China

来源：

关键词：

Resistance; TP53; EGFR amplification;

D O I：

10.1016/j.jtho.2018.08.1410

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P2.13-15

引用

页码：S803 / S804

页数：2